Akèy › Kansè Poumon ki pa ti selil › Florid › Tampa
Etid klinik pou Kansè Poumon ki pa ti selil nan Tampa, FL
51 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Tampa (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 2/3
- Moffitt Cancer Center /ID# 276785, Tampa
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Moffitt Cancer Center, Tampa
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #8, Tampa
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Moffitt Cancer Center-International Plaza, Tampa
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- ak 1 plis
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- Moffit Cancer Centre, Tampa
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Ap rekriteFaz 1
- ALX Center 7, Tampa
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
- H Lee Moffitt Cancer Center and Research Institute, Tampa
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Moffitt Cancer Center, Tampa
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Florida Cancer Specialists, Tampa
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Moffitt Cancer Center, Tampa
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Ap rekriteFaz 3
- H. Lee Moffitt Cancer Center & Research Institute, Tampa
- Local Institution - 0647, Tampa
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Ap rekriteFaz 2/3
- H. Lee Moffit Cancer center and research institute, Tampa
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Moffitt Cancer Center and Research Institute, Tampa
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- James A. Haley Veterans Hospital, Tampa
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Ap rekriteFaz 1/2
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Tampa
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Moffitt Cancer Center and Research Institute, Tampa
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Ap rekriteFaz 3
- Moffitt Cancer Center, Tampa
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 1/2
- Moffit Cancer Center, Tampa
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Ap rekriteFaz 3
- Moffit Cancer Center, Tampa
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- H Lee Moffitt Cancer Center and Research Institute, Tampa
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Ap rekriteFaz 2
- H Lee Moffitt Cancer Center and Research Institute, Tampa
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Ap rekriteFaz 3
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Ap rekriteFaz 1/2
- Moffitt Cancer Center and Research Institute, Tampa
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Lee Moffitt Cancer Center, Tampa
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Moffitt Cancer Center, Tampa
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Ap rekriteFaz 2
- Moffit Cancer Center, Tampa
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Tampa
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Tampa
- Kansè nan tete43 etid
- Kansè (tout kalite)39 etid
- Kansè kolorektal34 etid
- Leksemi mieloïd egi29 etid
- Kansè Metastatik29 etid
- Kansè poumon29 etid
- Kansè pankreyas26 etid
- Kansè ovè21 etid
- Melanom19 etid
- Sendwòm myelodisplastik19 etid
- Kansè pwostat18 etid
- Ensifizyans kadyak18 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.